Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

Seban, Romain-David; Nemer, John S.; Marabelle, Aurélien; Yeh, Randy; Deutsch, Éric; Ammari, Samy; Moya‐Plana, Antoine; Mokrane, Fatima-Zohra; Gartrell, Robyn D.; Finkel, Grace G.; Barker, Luke W.; Bigorgne, Amélie; Schwartz, Lawrence H.; Saenger, Yvonne M.; Robert, Caroline; Dercle, Laurent

doi:10.1007/s00259-019-04411-7

Cited by 100 publications

(90 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the paradigm shift of immunotherapy, authors have evaluated the potential role of appraising host metabolism in lymphoid tissues such as the bone marrow. They have demonstrated that increased bone marrow metabolism is associated with shorter overall survival and systemic immune suppression (41,42).…”

Section: Metabolic Prognostic Factorsmentioning

confidence: 99%

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients’ outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro- D -glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomical and metabolic information that complement each other. At initial staging, 18F-FDG PET/CT enhances the detection of extravesical disease, particularly in patients classified as oligometastatic by conventional imaging. 18F-FDG PET/CT has value in monitoring response to neoadjuvant and systemic chemotherapy, as well as in localizing relapse after treatment. In the new era of immunotherapy, 18F-FDG PET/CT may also be useful to monitor treatment efficacy as well as to detect immune-related adverse events. With the advent of artificial intelligence techniques such as radiomics and deep learning, these hybrid medical images can be mined for quantitative data, providing incremental value over current standard-of-care clinical and biological data. This approach has the potential to produce a major paradigm shift toward data-driven precision medicine with the ultimate goal of personalized medicine. In this review, we highlight current literature reporting the role of 18F-FDG PET in supporting personalized management decisions for patients with MIBC. Specific topics reviewed include the incremental value of 18F-FDG PET in prognostication, pre-operative planning, response assessment, prediction of recurrence, and diagnosing drug toxicity.

show abstract

Section: Metabolic Prognostic Factorsmentioning

confidence: 99%

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients with UVM at the highest risk for progression to metastatic disease [25,26], often results in high rates of mortality; effective prognostic indicators used to evaluate the survival of patients with UVM are limited [27,28]. In the present study, the most important discovery is reported that CIB1 as a potential diagnostic and prognostic factor in patients with UVM and might shed light on the UVM treatment by targeting CIB1.…”

Section: Discussionmentioning

confidence: 60%

CIB1 as a potential diagnosis and prognosis biomarker in uveal melanoma

Wang

Liu

Guo

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundUveal melanoma (UVM) is the most common primary intraocular tumor in adults. However, identification of the effective biomarker for the diagnosis and treatment of UVM remain to be explored. Calcium and integrin-binding protein 1 (CIB1) is emerging as an important mediator in carcinogenesis and tumor progression. In the present study, we aim to determine the contribution of CIB1 in the diagnosis of UVM.MethodsImmumohistochemical staining is used to detect the CIB1 expression level, while Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and UALCAN online tools were used to further analyze patient survival and CIB1 correlation genes in UVM. Integrative analysis using STRING and GeneMANIA predicted the correlated genes with CIB1 in UVM.ResultsTo the best of our knowledge the novel observations identified in the present study reveal that CIB1 expression level in UVM was significantly enhanced when compared with that in paracancerous tissues. A higher CIB1 expression level resulted in a significant worse disease free survival as well as overall survival. Moreover, survival probability of patients with UVM was associated with body weight and gender of the the patients. The correlated genes with CIB1 in UVM, and the similarity of the genes in UVM expression and survival heatmap was verified. Furthermore, Gene ontology enrichment analysis revealed that CIB1 and its correlated genes are significantly enriched in ITGA2B-ITGB3-CIB1 complex, regulation of intracellular protein transport and regulation of ion transport.ConclusionsTaken together, our novel findings suggested that CIB1 might be a potential diagnostic predictor for UVM, and might contribute to the potential strategy for UVM treatment by targeting CIB1.# These authors contributed equally to this work

show abstract

“…In a previous study, in which Seban and colleagues exploited data of 55 patients from two centers, TMTV and BLR, with cutoffs corresponding to their median values, were combined to yield three groups of patients with significantly different prognoses. Median OS were 13.9 months for the high-risk group (TMTV > 25cm 3 [26]. One limitation is that many patients had received prior systemic treatments or radiotherapy [22,26], which might have an impact on BLR.…”

Section: Association Between Baseline 18f-fdg Pet/ct Imaging and Outcmentioning

confidence: 99%

“…Median OS were 13.9 months for the high-risk group (TMTV > 25cm 3 [26]. One limitation is that many patients had received prior systemic treatments or radiotherapy [22,26], which might have an impact on BLR. It will be important to confirm the findings in series of first-line anti-PD-1 therapy and to assess the value of BLR compared with other biomarkers, such as dNLR or other inflammatory markers [8].…”

Section: Association Between Baseline 18f-fdg Pet/ct Imaging and Outcmentioning

confidence: 99%

Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?

Hindié

2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

Cited by 100 publications

References 48 publications

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

CIB1 as a potential diagnosis and prognosis biomarker in uveal melanoma

Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?

Contact Info

Product

Resources

About